Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201204039 Principal Investigator: Schroeder, Mark
Title: Expanded Access Program of Ponatinib (AP24534) for Patients with Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
Phase: N/A Disease Site: Myeloid and Monocytic Leukemia
Participating Site(s):
 
Main Campus
Map and Directions		 West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purpose of this research study is to give patient's with Chronic Myeloid Leukemia (CML) or Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) access to an experimental drug called ponatinib because other standard treatments haven’t worked or are no longer working for treatment of their leukemia. Ponatinib is being studied as a possible cancer treatment for CML and Ph+ ALL.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)